<DOC>
	<DOC>NCT02531568</DOC>
	<brief_summary>The purpose of this study is to evaluate the effects of MT-3995 on the PK of warfarin</brief_summary>
	<brief_title>Drug Interaction Study of Warfarin and MT-3995</brief_title>
	<detailed_description>The purpose of this study is to evaluate the potential effects of multiple once daily doses of MT-3995 on the PK of (S)-warfarin and (R)-warfarin after single-dose administration of racemic warfarin</detailed_description>
	<mesh_term>Warfarin</mesh_term>
	<criteria>Able and willing to provide written informed consent to participate in this study Healthy, free from clinically significant illness or disease White Caucasian male or female, aged 18 to 55 years Body weight ranging from 50 (females) and 60 (males) to110 kg (inclusive) Must have coagulation test results (including international normalised ratio [INR] and activated partial thromboplastin time [aPTT]) within the laboratory reference range at Screening. Presence or history of serious adverse reaction or allergy to any medicinal product Known contraindication or adverse reaction to warfarin. Presence of Cytochrome P450 2C9 (CYP2C9) and Vitamin K epoxide reductase complex subunit 1 (VKORC1) genetic polymorphisms that are known to increase warfarin sensitivity at Screening. Known contraindications to heparin administration. Known contraindication to parenteral vitamin K administration.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>October 2015</verification_date>
</DOC>